Seven kinds of RAD52i have been proposed, and some of these compounds are approved by the FDA [43], indicating that RAD52i is an attractive approach for BRCA1-, BRCA2-, RAD51 paralog-, and PALB2-deficient cancer [3,14]. This evidence concerns the gene PALB2 and cancer.